At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Metformindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Metformin for Age-Related Macular Degeneration and 3 related conditions. Completed, enrolled 66 participants across 12 sites.
Detailed Summary
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
CountriesUnited States
CollaboratorsSan Francisco Veterans Affairs Medical Center, VA Palo Alto Health Care System, University of California, Davis, University of California, San Diego, Northwestern University, University of Illinois at Chicago, Retinal Consultants Medical Group, Retina Health Center, California Retina Consultants, Oregon Health and Science University
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartApr 2016
Primary CompletionApr 2022
Study CompletionOct 2022
TodayJul 2026
First PostedFeb 18, 2016
Enrollment StartApr 1, 2016
Primary CompletionApr 1, 2022
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 10.4 years ago
Interventions
Metformindrug